| CASE REPORT |
|
| Year : 2022 | Volume
: 9
| Issue : 4 | Page : 149-152 |
|
|
The efficacy of sorafenib after progression on atezolizumab and bevacizumab combination therapy in a patient with advanced hepatocellular carcinoma
Yun-Tzu Lin, Hung-Chang Wu
Division of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan
Correspondence Address:
Dr. Yun-Tzu Lin
Division of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical Center, No. 901, Zhonghua Road, Yongkang, Tainan City 710402
Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/2311-3006.362637
|
|
|
Sorafenib was approved for the treatment of hepatocellular carcinoma more than 10 years ago; however, the efficacy is limited. The IMbrave150 trial demonstrated better overall survival and progression-free survival with atezolizumab plus bevacizumab combination therapy compared to sorafenib, and so it has become the choice of first-line treatment. However, the optimal choice of subsequent therapy after atezolizumab plus bevacizumab is unknown. We present a case with advanced hepatocellular carcinoma who achieved a complete response for more than 2 years under sorafenib treatment after progression with atezolizumab and bevacizumab combination therapy.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
